Singapore Patent for babyLance

 MediPurpose recently received approval of its application for patent protection of its babyLance infant heel incision device from the Intellectual Property Office of Singapore (IPOS). The IPOS issued MediPurpose a Certificate of Grant of Patent Number 167188. The device's patent approval is currently pending in several other countries.
Launched in July 2010, babyLance is a single-use heel incision device utilised to obtain a blood sample from the heels of newborn (babyLance BLN) and preemie (babyLance BLP) infants. The IPOS patent protects the unique design of the babyLance infant heel incision device, which earned it a U.S. FDA 510(K) clearance with sharps prevention indications—the first infant heel stick to earn such a distinction. These sharps prevention indications include (a) a locking mechanism to prevent accidental activation of the device, (b) a housing that conceals the blade before and after the device is used, (c) an internal spring that automatically retracts the blade after use, and (d) a stop feature that disables the device after a single use.
Source: MediPurpose (www.medipurpose.com)